This page covers some of the diagnostics tools and scribing tools in healthcare using generative AI but with specific focus on tools extracting audio data from various sources including sensors, consensual recordings of speech or biological sounds. The list spans tools across all stages of maturity right from pre-clinical research prototypes to FDA-cleared or CE-marked commercial products. Entries are organised by primary clinical domain. The time-frame for this compilation spans tools launched between January 2013 and December 2025. It does not yet reflect tools launched in 2026.
Respiratory health Includes tools that use cough, breath, or lung sounds for screening, diagnosis or monitoring of respiratory conditions such as asthma, COPD, pneumonia, or tuberculosis.
Mental health Includes voice and speech biomarker tools validated or designed for depression, anxiety, bipolar disorder, PTSD, or general mental wellness screening.
Neurological health Includes speech and language analysis tools used for cognitive decline, Parkinson's disease, Alzheimer's, ALS, aphasia or other neurological and neurodegenerative conditions.
Cardiovascular health Includes tools using heart sounds, lung sounds or voice biomarkers associated with cardiac conditions such as arrhythmias, murmurs, heart failure, or hypertension.
Hearing health Includes AI-enhanced hearing aids, audiometric screening apps, sound therapy platforms and tools that analyse ambient sound for hearing loss management or rehabilitation.
Clinical documentation Includes ambient AI scribes, clinical speech recognition tools and call-audio documentation systems used by clinicians for note generation (these are not diagnostic tools).
Foundation models Includes large pre-trained audio or speech models specifically relevant to healthcare (open-source or proprietary).
Notes Kintsugi shut down commercial operations in 2025 after spending approximately $16 million on FDA regulatory submissions. Its voice biomarker models and scientific methodologies were open-sourced. Beyond Verbal was acquired by and merged into Vocalis Health in December 2019 and no longer operates as an independent product.
References
